A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

HIV Infections Clinical Trial

Official title:

A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virologic Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00102206
• Other study ID #: P1053
• Secondary ID: 10131PACTG P1053
• Status: Completed
• Phase: Phase 2
• Est. completion date: May 2007

Study information

• Verified date: October 2021
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.

Description:

HIV infected children and adolescents on anti-HIV treatment regimens have traditionally had more difficulty with non-adherence and drug resistance than adults, often resulting in virologic failure. Additionally, HIV infected children with extensive exposure to antiretrovirals (ARVs) are likely to have fewer therapeutic options for salvage therapy, and their physicians find it difficult to choose regimens that will keep the HIV infection under control. This study will compare the efficacy of three 4-drug ARV salvage regimens in treatment-experienced, HIV infected children and adolescents who have experienced virologic failure.

This study will last at least 96 weeks. Participants will be randomly assigned to one of three groups. Group 1A will receive a dual-PI based regimen of lopinavir/ritonavir (LPV/r), saquinavir (SQV), and the NRTIs emtricitabine (FTC) and abacavir sulfate (ABC). Group 1B will receive a dual-PI based regimen of LPV/r, SQV, FTC, and tenofovir disoproxil fumarate (TDF). Group 2 will receive an NRTI-only regimen of ABC, lamivudine, zidovudine, and TDF.

There will be 11 study visits during Step I of this study. Medical history, a physical exam, and blood collection will occur at all visits. Dual-energy x-ray absorptiometry (DEXA) scans will occur at study entry and at Weeks 24, 48, 72, and 96. Urine collection will occur at most visits; participants will also take part in adherence modules at most visits. Participants will be asked to complete a pill count form at Weeks 4 and 24. Additionally, some study participants will be asked to participate in an intensive pharmacokinetics study at Week 4.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: May 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 21 Years

Eligibility

Inclusion Criteria for Step I:

• HIV infected

• No currently available therapeutic options that would likely result in long-term suppression of virus to less than 400 copies/ml

• Two measurements within 4 months prior to screening and at screening of either CD4% of less than 15% and HIV viral load of greater than 10,000 copies/ml OR HIV viral load greater than 30,000 copies/ml

• Previous exposure to non-nucleoside reverse transcriptase inhibitors (NNRTIs), NRTIs, and PIs AND have experienced virologic failure. More information on previous treatment regimen requirements is available in the protocol.

• Prior or current virologic failure with genotypic or phenotypic resistance OR historical virologic failure with a PI- or NNRTI-containing regimen

• Resistance to 2 or more drugs in most recent treatment regimen within 26 weeks prior to study screening

• Able and willing to swallow study medications

• Parent or guardian willing to provide informed consent, if applicable

• Willing to use acceptable methods of contraception

Exclusion Criteria for Step I:

• Previous cumulative exposure to TDF for more than 24 weeks OR more than 14 days of TDF exposure during the 24 weeks prior to study entry

• Grade 1 lipase or higher within 28 days prior to study entry

• Grade 3 or higher laboratory abnormality (except for lipase) within 28 days prior to study entry

• History of allergy or hypersensitivity to any of the study drugs

• Active CDC Stage C opportunistic infection or serious bacterial infection requiring therapy at the time of screening

• Chemotherapy for active cancer

• Require certain medications

• Abnormal kidney function

• Any clinically significant diseases other than HIV infection or findings during medical history screening that, in the opinion of the investigator, may interfere with the study

• Pregnancy or breastfeeding

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Abacavir sulfate

• Emtricitabine

• Lamivudine

• Lopinavir/ritonavir

• Saquinavir

• Tenofovir disoproxil fumarate

• Zidovudine

Locations

Country	Name	City	State
United States	Chicago Children's CRS	Chicago	Illinois
United States	DUMC Ped. CRS	Durham	North Carolina
United States	Columbia IMPAACT CRS	New York	New York
United States	SUNY Stony Brook NICHD CRS	Stony Brook	New York

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Brogly S, Williams P, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K; PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005 May 11;293(18):2213-20. — View Citation

Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs. 2002;4(9):581-607. Review. — View Citation

Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs. 2004;6(3):147-59. Review. — View Citation

Neely M, Kovacs A. Management of Antiretroviral Therapy in Neonates, Children, and Adolescents. Curr Infect Dis Rep. 2003 Dec;5(6):521-530. — View Citation

Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. 1999 Jul 30;13(11):F71-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability of dual PI-based HAART versus multi-NRTI HAART salvage regimens (time to first intolerant event)
Primary	95% confidence interval (CI) for change in CD4% computed for PI-containing groups versus PI-sparing group
Primary	95% CI for change in BMD (both percent change in BMD and change in z-score from baseline) for each treatment group
Secondary	HIV-1 RNA
Secondary	growth and development markers
Secondary	toxicity
Secondary	adherence
Secondary	pharmacokinetics
Secondary	special virologic and immunologic parameters

External Links

•   Click here for more information about HIV treatment regimen failure
•   Haga clic aquí para ver información sobre este ensayo clínico en español.